SEC Form 4 · accession 0001179110-16-028838
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Uli Hacksell
Officer — President and CEO · Director
Period of report
Aug 17, 2016
Accepted (ET)
Aug 19, 2016 · 9:16 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.77 | Aug 17, 2016 | A | 130,000 | A | — | Aug 16, 2026 | Common Stock | 130,000 | 130,000 | D |
Explanation of responses
- F132,500 of the shares underlying the option shall vest and become exercisable on August 17, 2017; the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter beginning on September 17, 2017, subject to the Reporting Person's continued service with the Issuer on each such date.